Herantis Pharma Oyj
OMXH:HRTIS
Fundamental Analysis

Revenue & Expenses Breakdown
Herantis Pharma Oyj
Balance Sheet Decomposition
Herantis Pharma Oyj
Current Assets | 2.6m |
Cash & Short-Term Investments | 2.1m |
Receivables | 208.4k |
Other Current Assets | 228.6k |
Free Cash Flow Analysis
Herantis Pharma Oyj
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Herantis Pharma Oyj
Revenue
|
0
EUR
|
Operating Expenses
|
-5m
EUR
|
Operating Income
|
-5m
EUR
|
Other Expenses
|
87.2k
EUR
|
Net Income
|
-4.9m
EUR
|
HRTIS Profitability Score
Profitability Due Diligence
Herantis Pharma Oyj's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Herantis Pharma Oyj's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
HRTIS Solvency Score
Solvency Due Diligence
Herantis Pharma Oyj's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Herantis Pharma Oyj's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HRTIS Price Targets Summary
Herantis Pharma Oyj
According to Wall Street analysts, the average 1-year price target for HRTIS is 1.326 EUR with a low forecast of 0.707 EUR and a high forecast of 1.995 EUR.
Dividends
Current shareholder yield for HRTIS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?